The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011, Eur J Cancer, vol.49, pp.2126-2159, 2013. ,
KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment, Mod Pathol, vol.25, pp.731-740, 2012. ,
About the possible origin and mechanism of circulating DNA apoptosis and active DNA release, Clin Chim Acta, vol.313, pp.139-181, 2001. ,
Circulating DNA. Its origin and fluctuation, Ann N Y Acad Sci, vol.1137, pp.18-26, 2008. ,
Apoptotic markers in cancer, Clin Biochem, vol.37, pp.605-622, 2004. ,
Circulating apoptotic markers in the management of nonsmall cell lung cancer, Cancer Biomark, vol.6, pp.197-210, 2010. ,
Detection of freecirculating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis, Int J Cancer, vol.100, pp.542-550, 2002. ,
Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, pp.1722-1753, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299581
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nat Med, vol.20, pp.430-435, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02168071
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, vol.486, pp.532-538, 2012. ,
Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, pp.224-248, 2014. ,
Multiplex PicoliterDroplet Digital PCR for quantitative assessment of DNA integrity in clinical samples, Clin Chem, vol.59, pp.815-838, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299583
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations, Proc Natl Acad Sci, vol.100, pp.8817-8839, 2003. ,
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage, Nat Med, vol.20, pp.548-54, 2014. ,
Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing, JAMA Oncol, vol.1, pp.814-823, 2015. ,
Detection and quantification of rare mutations with massively parallel sequencing, Proc Natl Acad Sci U S A, vol.108, pp.9530-9535, 2011. ,
Circulating cell free DNA: preanalytical considerations, Clin Chim Acta, vol.424, pp.222-252, 2013. ,
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, Nat Med, 2015. ,
Predictors of clonal evolution in metastatic colorectal cancer patients, J Clin Oncol, vol.33, issue.20, 2015. ,
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulatingfree tumor DNA as a surrogate for determination of EGFR status, J Thorac Oncol, vol.9, pp.1345-53, 2014. ,
Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis, Cancer Epidemiol Biomarkers Prev, vol.24, pp.206-218, 2015. ,
Diagnostic accuracy of noninvasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA, Clin Chem, vol.61, pp.1191-1197, 2015. ,
Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial, JAMA Oncol, vol.1, pp.149-57, 2015. ,
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, vol.13, pp.239-285, 2012. ,
Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer, Cancer, 2015. ,
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients, Nat Commun, vol.6, p.7686, 2015. ,
Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer, Int J Cancer, vol.135, pp.2984-91, 2014. ,
Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan, Clin Cancer Res, vol.18, pp.1177-85, 2012. ,
Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC), J Clin Oncol, vol.32, issue.1, p.11015, 2014. ,
Assessment of circulating free DNA concentration as a prognostic and predictive biomarker in a large cohort of non-small cell lung cancer treated by platinum-based chemotherapy, J Clin Oncol, vol.33, issue.20, 2015. ,
K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer, Eur J Surg Oncol, vol.36, pp.657-62, 2010. ,
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann Oncol, vol.26, pp.1715-1737, 2015. ,
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment, Ann Oncol, vol.26, pp.731-737, 2015. ,
Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy, Clin Cancer Res, vol.21, pp.1087-97, 2015. ,
Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy, Clin Cancer Res, vol.21, pp.3196-203, 2015. ,
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA, Clin Cancer Res, vol.20, pp.1698-705, 2014. ,
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat Med, vol.21, pp.560-562, 2015. ,
Liquid biopsies in lung cancer: the new ambrosia of researchers, Biochim Biophys Acta, vol.1846, pp.539-585, 2014. ,
Monitoring minimal residual disease (MRD) by KRAS mutation burden in urinary or plasma circulating tumor (ct) DNA in colorectal cancer (CCR) patients with resectable liver metastases, J Clin Oncol, vol.33, issue.20, 2015. ,